| Quantity: | |
|---|---|
Dotinurad (CAS: 1285572-51-1) is a novel and potent selective urate reabsorption inhibitor (SURI) designed to lower serum uric acid by inhibiting urate transporter-1 (URAT1) in the renal proximal tubules. By specifically blocking URAT1-mediated uric acid reabsorption, Dotinurad promotes uric acid excretion and effectively reduces systemic urate levels, making it a promising active pharmaceutical ingredient for hyperuricemia and gout management.
Dotinurad exhibits a well-characterized mechanism of action and a pharmacological profile comparable to established urate-lowering agents, with demonstrated efficacy across multiple clinical studies. In long-term trials, patients treated with Dotinurad achieve significant reductions in serum uric acid, with a high proportion achieving target urate levels ≤6.0 mg/dL, supporting its potential as a durable and effective treatment modality.
This API is suitable for pharmaceutical R&D, formulation development, and clinical pipeline projects focused on respiratory, metabolic, and renal disorders associated with elevated urate levels. Due to its high selectivity and favorable safety profile, Dotinurad is of particular interest for companies advancing next-generation therapies for gout and chronic hyperuricemia.
Dotinurad is an effective selective urate reabsorption inhibitor.
5.00kg/bag/drum, 5.00kg/bag ,2 bags/drum or according to customer’s requirements.
Dotinurad (CAS: 1285572-51-1) is a novel and potent selective urate reabsorption inhibitor (SURI) designed to lower serum uric acid by inhibiting urate transporter-1 (URAT1) in the renal proximal tubules. By specifically blocking URAT1-mediated uric acid reabsorption, Dotinurad promotes uric acid excretion and effectively reduces systemic urate levels, making it a promising active pharmaceutical ingredient for hyperuricemia and gout management.
Dotinurad exhibits a well-characterized mechanism of action and a pharmacological profile comparable to established urate-lowering agents, with demonstrated efficacy across multiple clinical studies. In long-term trials, patients treated with Dotinurad achieve significant reductions in serum uric acid, with a high proportion achieving target urate levels ≤6.0 mg/dL, supporting its potential as a durable and effective treatment modality.
This API is suitable for pharmaceutical R&D, formulation development, and clinical pipeline projects focused on respiratory, metabolic, and renal disorders associated with elevated urate levels. Due to its high selectivity and favorable safety profile, Dotinurad is of particular interest for companies advancing next-generation therapies for gout and chronic hyperuricemia.
Dotinurad is an effective selective urate reabsorption inhibitor.
5.00kg/bag/drum, 5.00kg/bag ,2 bags/drum or according to customer’s requirements.
